Nxera Pharma & Santhera Pharmaceuticals

Nxera Pharma: Nxera Pharma holds exclusive rights to AGAMREE in Japan, South Korea, Australia, and New Zealand, and plans to submit a Marketing Authorization Application in South Korea during 2026. This designation will accelerate the review process for AGAMREE.

Santhera Pharmaceuticals: Santhera Pharmaceuticals will receive sales, milestone payments, and royalties from the net sales of AGAMREE in South Korea, Japan, Australia, and New Zealand due to the licensing agreement with Nxera Pharma The Orphan Drug Designation and Global Innovative Products on Fast Track designation for AGAMREE in South Korea are positive developments for the company.